Vivo Ventures | Activity | F4
Vivo Ventures Activity Every public signal F4 has attached to this firm, with sources and cross-entity links.
News
Marked its 30th anniversary with a new philanthropic initiative. 30th anniversary philanthropic initiative
Medtronic completed its $550M acquisition of portfolio company Scientia Vascular. Investment
Led Full-Life Technologies' US$150M financing (Series D equity + debt) to advance its radiotherapeutics pipeline. Full-Life Technologies
Exit
Portfolio company Ajax Therapeutics agreed to be acquired by Eli Lilly for up to $2.3B. Ajax Therapeutics
Investment
Co-led Oricell Therapeutics' $110M+ pre-IPO financing for solid-tumor CAR-T therapies, alongside Beijing Medical and Health Care Industry Investment Fund and Qiming Venture Partners. Oricell Therapeutics
Exit
Portfolio company Soleno Therapeutics agreed to be acquired by Neurocrine Biosciences for $2.9B. Soleno Therapeutics
Exit
Portfolio company Terns Pharmaceuticals agreed to be acquired by Merck for $6.7B. Terns Pharmaceuticals
Investment
Agreed to acquire Dutscher Group, a €400M+ revenue pan-European lab-supplies distributor, from LBO France — Vivo Capital's first European buyout. Dutscher Group
New Fund
Closed its dedicated public-equity fund with commitments of over $740M. Dedicated Opportunity (public equity) Fund